Changes in Hong Kong stocks | Hebo Pharmaceutical-B (02142) rose by nearly 15%; HBM7004 clinical application approved by the State Drug Administration for advanced solid tumor treatment

The Zhitong Finance App learned that Hebo Pharmaceutical-B (02142) rose by nearly 15%. As of press release, it had risen 11.73% to HK$16.19, with a turnover of HK$278 million.

According to the news, Hebo Pharmaceutical announced that the clinical trial application for HBM7004 as a new drug for the treatment of advanced solid tumors has been approved by the State Drug Administration. This is another important development since the company announced on May 8, 2026 that it obtained approval from the US FDA for its IND application.

According to reports, HBM7004 is a novel b7H4xCD3 bispecific antibody developed from the Group's proprietary HBICE® platform to provide differentiated solutions for cancer immunotherapy in terms of efficacy and safety. The development of the HBM7004 further highlights the flexible applicability and plug-and-play advantages of the HBICE® platform.